Welcome to our dedicated page for Lyell Immunopharma SEC filings (Ticker: LYEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lyell Immunopharma filings document the regulatory record of a Nasdaq-listed clinical biotechnology company developing next-generation CAR T-cell therapies. Its 8-K reports furnish operating results and business updates for ronde-cel in large B-cell lymphoma and LYL273 in metastatic colorectal cancer and other GCC-expressing cancers, along with cash, financing and clinical-program disclosures.
The company’s filings also cover material agreements, including licensing rights for LYL273, and governance matters such as annual-meeting proposals, director elections, auditor ratification, executive compensation votes, officer appointments and compensatory arrangements. Securities disclosures identify Lyell’s common stock listed on the Nasdaq Global Select Market.
Lyell Immunopharma director Sumant Ramachandra reported an equity award and updated holdings. He received an option grant covering 9,250 shares of common stock at an exercise price of $13.22 per share, expiring on June 9, 2036.
The option vests on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before it if his board service ends at that meeting) or the first anniversary of that date, contingent on continuous service. In addition, 10,000 shares of common stock are held indirectly by the Sumant Ramachandra Rev Trust DTD 01/24/12, where he is grantor and trustee. All share amounts reflect a 1-for-20 reverse stock split effected on May 30, 2025.
Lyell Immunopharma director Elizabeth G. Nabel received a grant of stock options covering 9,250 shares of common stock. The options have an exercise price of $13.22 per share and were awarded as a compensation grant, not an open-market purchase or sale.
The options vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before that date if her board service ends at that meeting), or the first anniversary of June 10, 2026, provided she continues serving as a director. The options expire on June 9, 2036, and following this grant she holds options to acquire 9,250 shares.
Lyell Immunopharma director Richard Klausner received a grant of 9,250 stock options for common stock, each with a $13.22 exercise price and expiring on June 9, 2036. This is a compensation-related award rather than an open-market purchase.
The options will vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before it if he leaves the board at that meeting) or the first anniversary of that date, assuming continuous service. Following the reporting date, he held 148,391 common shares directly and 42,166 shares indirectly through family and Delaware trusts, with beneficial ownership of the Delaware trusts disclaimed except for any pecuniary interest. All share amounts reflect a 1-for-20 reverse stock split effective May 30, 2025.
Lyell Immunopharma director Cathy Friedman received a compensatory stock option grant for 9,250 shares of common stock. The option has an exercise price of $13.22 per share and expires on June 9, 2036. All share amounts reflect Lyell’s 1-for-20 reverse stock split effective May 30, 2025.
The option will vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before that date if her board service ends at that meeting) or the first anniversary of June 10, 2026, subject to her continuous service. The filing also reports 5,000 shares held by The Duane Irrevocable Trust 2020 and 11,818 shares held by the Duane Family Trust, where Friedman is a trustee and disclaims beneficial ownership except to any pecuniary interest.
Lyell Immunopharma director Otis W. Brawley reported a new stock option grant. He received options to buy 9,250 shares of common stock at an exercise price of $13.22 per share, expiring on June 9, 2036.
The options vest on the earlier of the next annual stockholder meeting after June 10, 2026 or the first anniversary of that date, subject to his continued service as a director. Following the reported transactions, he holds 1,782 shares of common stock directly. All share amounts reflect a 1-for-20 reverse stock split effective May 30, 2025.
Lyell Immunopharma director Mark Bachleda received a grant of stock options for 9,250 shares of common stock. These options give him the right to buy 9,250 shares at an exercise price of $13.22 per share and expire on June 9, 2036.
The award is compensation-related and was not an open-market purchase. According to the vesting terms, all 9,250 option shares vest on the earlier of the next annual stockholder meeting after June 10, 2026, or the first anniversary of that date, provided he continues serving as a director through the vesting date.
Lyell Immunopharma Chief Medical Officer David Shook reported a small share sale primarily to cover taxes. On this Form 4, he sold 1,977 shares of common stock at $12.64 per share, with the shares automatically sold to satisfy tax withholding obligations from vested restricted stock units.
After this transaction, Shook directly owns 20,923 common shares, which includes 1,000 shares acquired on May 18, 2026 under Lyell’s 2021 Employee Stock Purchase Plan. The filing reflects a routine, tax-related disposition rather than a large discretionary sale.
ARCH-affiliated entities report beneficial ownership filing for Lyell Immunopharma common stock. The cover rows show shared voting and dispositive power over 3,247,162 shares for multiple ARCH entities and individuals. The percentage figures are calculated using 23,334,087 shares outstanding as of May 1, 2026.
The filing lists record ownership positions: AVF IX and related AVP entities hold record shares of 910,317 each in certain funds, while AVF XIII shows 1,426,528 shares. Reporting Persons disclaim beneficial ownership except for shares held of record.
Lyell Immunopharma, Inc. filing amends a Schedule 13G to report that MWG Caph Ltd and Milky Way Investments Group Ltd each beneficially own 1,008,116 shares of Common Stock, representing 4.3% of the class based on 23,328,390 shares outstanding reported in the company's DEF 14A filed April 24, 2026.
The cover page shows each Reporting Person has sole voting and sole dispositive power over the 1,008,116 shares. The amendment is signed by authorized representatives and updates the ownership disclosure for these related entities.
Lyell Immunopharma, Inc. Schedule 13G/A shows Explore Investments LLC and Jeffrey P. Bezos each report beneficial ownership of 1,529,054 shares of Lyell common stock, representing 6.6% of the outstanding shares. The percentage is calculated using 23,328,390 shares outstanding as of March 31, 2026, per the issuer's preliminary prospectus dated April 3, 2026. The filing states Explore is the direct holder and that Mr. Bezos may be deemed the beneficial owner as sole member of Explore. Signatures appear dated May 8, 2026.